Veloxion disposable resectoscope system for BPH surgery
Official title: Prospective, Single-Site, Single-Arm Evaluation of the Aulea Veloxion™ Disposable Resectoscope System for Operational Efficiency in Surgical Management of Benign Prostatic Hyperplasia (BPH)
Run by Chinese University of Hong Kong · NCT07728071 · Data updated 2026-11-12
This study tests whether the Veloxion disposable resectoscope helps perform endoscopic BPH surgery more efficiently and safely in men with moderate to large prostates.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 30 Years to 70 Years |
| Sex | Men only |
| Enrollment | 20 (estimated) |
| Sponsor | Chinese University of Hong Kong Academic / other |
| Locations | 1 site (Shatin) |
| Status | Recruiting |
| Started | October 2, 2026 |
| Main results expected | June 30, 2027 |
| Study ends | December 31, 2027 |
| Registry record updated | October 27, 2026 |
| Trial ID | NCT07728071 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Men aged 30-70 with symptomatic BPH and prostate volume 20–120 mL who are deemed suitable for endoscopic resection or vaporization and able to complete follow-up.
✕Probably not a fit
Patients with prostate cancer, recent prostate surgery or implants affecting anatomy, active untreated infection, coagulation problems, or significant comorbidity may not benefit from this device approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective, single-arm, single-site post-market device study evaluating the Veloxion disposable resectoscope used during endoscopic treatment of benign prostatic hyperplasia. The primary focus is operational efficiency and safety, with follow-up visits at 2 weeks and 1 month to capture safety data, device-related adverse events, any need for reinterventions, and usability feedback. All procedures use the device per the manufacturer’s instructions for use. Eligible participants are men aged 30-70 with symptomatic BPH and prostate volume between 20 and 120 mL who are suitable for endoscopic resection or vaporization. Exclusion criteria include prostate cancer requiring oncologic care, recent prostate surgery or implants affecting anatomy, active infection, coagulation issues, or significant medical comorbidity that would preclude anesthesia or endoscopy.
Why it matters
Potential benefit: If successful, patients could experience safer or quicker endoscopic BPH surgery with the Veloxion system and improved procedural efficiency.
How similar studies have gone: Prior post-market device evaluations in urology have shown variable but informative safety and usability signals for disposable endoscopic tools; this study adds prospective single-site data for Veloxion in BPH.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 30-70 years old with symptomatic BPH. * Prostate volume 20-120 mL (TRUS/MRI/US) * Suitable for endoscopic resection/vaporization per device IFU. * Able to consent and comply with follow-up to 1 month. Exclusion Criteria: * Known/suspected prostate cancer requiring oncologic management. * Prior prostate surgery impacting urethral anatomy within 12 months. * Prior implant affecting urethral anatomy. * Active UTI or untreated bacteriuria pre-op. * Uncorrectable coagulopathy; inability to manage antithrombotics. * Severe medical comorbidity precluding anesthesia or endoscopy.
Where it's running
-
Prince of Wales Hospital
Shatin, Hong Kong Recruiting
Study contacts
- Principal investigator: Qinyang LIU, MBBS, MSc, FRCSEd — Chinese University of Hong Kong
- Study coordinator: Alex Qinyang LIU, MBBS, MSc, FRCSEd
- Email: alexliu@surgery.cuhk.edu.hk
- Phone: +852-3505-2625
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
See if PuraStat after Aquablation reduces bleeding and speeds discharge
This study tests whether applying PuraStat after Aquablation can reduce bleeding and allow more patients to go home the same day.
-
Transurethral Thermodilatation vs Prostatic Urethral Lift for BPH in men 50–80
This study tests whether Prolieve can match UroLift in relieving BPH symptoms in men 50–80 who haven’t had enough relief from medicines.
-
Sonablate HIFU Registry for Prostate Cancer and BPH
This registry collects real-world data from men treated with Sonablate HIFU to see how well it works and how it affects urinary and sexual function over the long term.
-
Beacon Platform for HoLEP: Safer, Smarter Prostate Surgery
This trial tests whether the Beacon Platform can safely support the HoLEP procedure for men with enlarged prostates.
-
Ultra-minimally invasive prostate balloon dilation for men with BPH and significant obstruction
This study tests whether transrectal ultrasound–guided ultra-minimally invasive prostate balloon dilation can reduce urinary symptoms in men aged 40–80 with BPH and significant bladder outlet obstruction.
-
Comparing holmium and thulium laser prostate enucleation for enlarged prostate
This compares two laser operations—HoLEP and ThuLEP—to see which gives better symptom relief for men with an enlarged prostate (BPH) who need surgery.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.